Filing Details
- Accession Number:
- 0001104659-24-115867
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-08 16:15:05
- Reporting Period:
- 2024-11-06
- Accepted Time:
- 2024-11-08 16:15:05
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1649904 | Rhythm Pharmaceuticals Inc. | RYTM | Pharmaceutical Preparations (2834) | 462159271 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1873517 | J. Pamela Cramer | 222 Berkeley Street 12Th Floor Boston MA 02116 | Chief Human Resources Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-11-06 | 4,687 | $19.02 | 18,187 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-11-06 | 4,687 | $60.00 | 13,500 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2024-11-07 | 4,688 | $19.02 | 18,188 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-11-07 | 4,688 | $65.00 | 13,500 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Options (Right to buy) | Disposition | 2024-11-06 | 4,687 | $0.00 | 4,687 | $19.02 |
Common Stock | Stock Options (Right to buy) | Disposition | 2024-11-07 | 4,688 | $0.00 | 4,688 | $19.02 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
18,750 | 2031-07-25 | No | 4 | M | Direct | |
14,062 | 2031-07-25 | No | 4 | M | Direct |
Footnotes
- The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 10, 2024.
- The stock options were granted on July 26, 2021. 25% of the shares subject to the option vested and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest or have vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.